One of the major differences between GHRP 2 and GHRP 6 is that the latter increases hunger in you substantially, especially when you consume the supplement at regular intervals. Therefore, those looking to build muscles and lose excess fat may want to consider GHRP 2 as it is not known to build appetite in you to that extent. However, if your aim is to eat more and growth quickly then GHRP 6 based supplements is for you.
In 1999, seven adult patients with GH deficiency and LV failure received hexarelin administrations. The GH response to hexarelin was negligible in these patients. Moreover, hexarelin administration increased their left ventricular ejection fraction (LVEF) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output. For the first time, the acute administration of hexarelin proved to induce a positive inotropic effect in humans, which is GH independent and mediated by specific myocardial receptors for a GH secretagogue peptide.29 A subsequent study involving hexarelin administration to normal adults, severe GH-deficient patients (N = 7), and patients with severe ischemic DCM (N = 12) confirmed that the acute administration of hexarelin exerts a GH-independent positive inotropic effect likely mediated by specific GHRP myocardial receptors.30 This pioneering group subsequently evaluated the cardiac performances of the acute hexarelin administration (2.0 µg/kg, i.v.) in patients undergoing bypass surgery in comparison to patients given GH-releasing hormone, recombinant human GH, or placebo. The study concluded that the acute administration of hexarelin improved cardiac performance without any relevant variation in systemic vascular resistance and induced a reduction of wedge pressure and, significantly, that these cardiotropic effects were not shown by the other concurrent interventions.31

Five of the submissions did not support the proposal while the sixth submission did. The former contend that potential risks of inadvertent use of caffeine in those at risk of an adverse event will be increased if selection of an analgesic is made without the assistance or intervention of a healthcare professional. There was also concern that the proposed exemption may result in an increase in liver damage due to excessive consumption of such a product. This was likely to result from people abusing these products as a source of stimulants.

If you’re ready to see differences in your workout regimen, you may be curious how muscle peptides are associated with lean muscle gain and strength building. As a locally owned and operated company, Muscle Peptides Australia is committed to helping our clients across Australia achieve their fitness goals. Contact us to unlock your body’s real potential.


Healthy male Wistar rats (250–270 g) were purchased from the National Center for Animal Breeding (CENPALAB, Havana, Cuba). Animals were individually housed at the animals’ facility of the Center for Genetic Engineering and Biotechnology, Havana, Cuba, and maintained under controlled environmental conditions and light cycles (12/12 hrs). Rats were fed with standard laboratory rodent’s chow under no restriction. Following an acclimation week, the dorsum of the rats was conditioned to receive two controlled full-thickness wounds, under sodium pentobarbital (30 mg/kg) anesthesia. The cuts were generated with disposable 6 mm diameter punch biotomes (Acuderm, Ft. Lauderdale, USA). Two independent experiments were performed using the above described wound model. Thus, 10 rats ( wounds) were used for either GHRP-6 formulation or vehicle (1% CMC) groups in each experiment. Upon wounds induction the rats were randomly assigned to either group. The wounds were cleansed daily with saline, their contours traced on transparent plastic sheets and treated accordingly. Treatments were topically applied twice a day at the same hours during four days. Wounds closure dynamic was measured by planimetric analysis as described previously [16] using the ImageJ software, version 1.46r. Since the GHRP-6 intervention increased the rate of closure, the animals were terminated by anesthesia overdose on day five after wounding. Ulcers and a surrounding margin of intact skin (~5 mm) were collected and hemisectioned. One hemisection was preserved in RNA Later solution for further gene expression studies. The other hemisection was fixed in 10% buffered formalin, paraffin embedded, and 5-μm sectioned. The specimens were stained with hematoxylin/eosin (H/E) and Mallory trichrome to examine collagen deposit. Other slides were destined for immunohistochemistry (as described below).
to amend the Standard for the Uniform Scheduling of Medicines and Poisons to include vitamin D, as a single weekly dose of up to 175 micrograms (7000IU) per recommended dose, in Schedule 3 (noting that the wording "per recommended weekly dose" in the interim decision's proposed Schedule 3 entry should have read "per recommended single weekly dose"); and
Phenylephrine is a direct alpha-1 adrenergic agonist, with weak alpha-2 adrenergic agonist activity. It also has very weak beta-adrenergic effects, but at therapeutic doses there are no significant stimulating beta-1 adrenergic effects on the heart, or on the bronchial airways, or on peripheral blood vessels. This contrasts with pseudoephedrine, which has greater beta-adrenergic activity. The effect on the alpha-adrenergic receptors leads to local vasoconstriction and shrinking of mucous membranes. There is no anti-histamine effect. The drug is readily and completely absorbed following oral administration, undergoing extensive first pass metabolism in the intestinal wall and in the liver leading to some variability in individual pharmacokinetics. Nasal decongestion is apparent within 15 to 20 minutes and persists for up to 4 hours (AHFS 2007).

GHRH (1 μg/kg) plus GHRP-6 (1 μg/kg) is given intravenously at 0 minutes and blood drawn for GH sampling at 0 and 120 minutes [200]. GH releasing peptide-6 (GHRP-6) is an artificial hexapeptide [96] that activates the ghrelin receptor [98]. Combined administration of GHRP-6 and GHRH is the most potent stimulus to GH release, with excellent reproducibility and no serious side effects [96]. GHRH/GHRP-6 is a viable alternative to the ITT in patients with organic pituitary disease, however there is overlap between GH levels attained in the control group and severely GH-deficient patients. Since GHRH and GHRP act directly on the pituitary, it is possible that their administration restores GH secretion in patients with a deficiency of these secretagogues because of hypothalamic disease [201].
It is here that Growth Hormone Releasing Peptide 6, or Growth Hormone Releasing Hexapeptide comes into the picture. Also called as GHRP-6, it is a synthetic met-enkephalin analog. It includes unnatural D amino acids. It is instrumental in releasing growth hormone that helps in muscle recovery, strengthing of joints and tendons, and fat loss. It is distinct from Growth Hormone Releasing Hormone or GHRH which causes a higher amount of growth hormone to be secreted during the body normal secretion time. GHRP-6 on the other time will target a pulse and force the pituitary to release the growth hormone that is stored there. It helps a particular muscle group to achieve maximum growth.
As an athlete, you can also increase your dosage cycle for a period of 12 to 16 weeks at a time, to maximize your gains. Do so gradually if you opt to go this route. Make sure you increase your daily dosage (1 to 2 doses per day, etc.) gradually. Start off with lower dosage levels as well, and see how it interacts with your body. You don’t want to experience withdrawal, nor do you want to experience negative side effects when using Ipamorelin for longer dosage cycles. So, make sure you monitor your progress, see how you feel as you go, and make notes if/when you do experience negative side effects, so you can balance down to the proper dosage levels.

It is extremely important to create awareness among the masses, that procuring illegal drugs off the black market or the internet is an offence under the federal law, being guilty of which can lead to a long jail sentence. Secondly, people should be made aware of the fact that drugs procured through illegal means may be fake or adulterated with other steroids or addictive agents.


For example, insufficient protein or calories can cause IGF-1 to plummet, while ample calories can cause IGF-1 to increase. For example, one study of women who fed with excess calories over and above their normal metabolic rate noted a 19% increase in IGF-1 after two weeks of overfeeding, with 46% of the weight gain from  lean mass and 54% from bodyfat. Fasting insulin doubled in these women, and testosterone levels also significantly increased.
In studies GHRP-6 has shown biological actions similar to the naturally occurring hunger stimulating peptide ghrelin. Its main use is to promote food intake by stimulating hunger and aid in energy metabolism. It can be used in the treatment of GH deficiency as well as cachexia, eating disorders and obesity. GHRP-6 is a synthetic met-enkephalin (a naturally occurring opioid growth factor) analog. GHRP-6 contains D-amino acids that are entirely synthetic, lacks opioid activity, and shares no sequence relation with GHRH. It has also been shown that GHRP-6 can lead to re-stimulation of the natural production of HGH.
Myocardial ischemia/reperfusion damage entails multiple molecular and biochemical mechanisms that each alone is sufficiently injurious to disturb an organ whose mechanical performance is dependent upon the stability of ionic/electrical pumps. Oxidative stress, intracellular calcium overload, pH changes, mitochondrial dysfunction, inflammation, and excessive neurohormones are part of an interactive and self-perpetuating continuum of the myocardial injury cascade (Figure 1). The evidences obtained along the years of experimental screening of the synthetic GHRP suggest that each single member of this family of peptides is able to simultaneously counteract different injurious operators in the myocardial ischemic event.
Growth hormone (GH) was first identified for its notable effect on longitudinal growth. Subsequent research revealed that the GH has anabolic effects on protein, lipid, and carbohydrate metabolism. GH replacement therapy, using recombinant GH, is therefore used to treat individuals with short stature due to a variety of conditions. However, GH replacement therapy suffers from significant drawbacks such as low bioavailability and side effects. Moreover, most GH-deficient individuals exhibit a secretory defect rather than a primary deficiency in GH production. Research seeking a better drug to replace GH was therefore extensively active in the 1980s and 1990s.
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; e) the potential for abuse of a substance; f) any other matters that the Secretary considers necessary to protect the public health.
Hexarelin via CD36 occupation increases the expression of multiple genes involved in fatty acid mobilization in adipocytes toward the mitochondrial oxidative phosphorylation, and many of these upregulated genes are known targets of PPARγ. Consistent with this, electron microscopy of hexarelin-treated adipocytes reflects highly organized cristae formation that spans the entire width of mitochondria, with a concomitant cytochrome c oxidase activity enhancement. Although this signaling and activation cascade has not been described for myocardial cells so far, the potential existence of these phosphorylative and mitochondriogenic mechanisms in the heart, and its potential amplification by GHRP ligands, may eventually contribute to myocardial salvage during critical ischemia periods.47 In a more recent study based on a myocardial infarction model, and addressed to examine whether hexarelin treatment can compensate for ghrelin deficiency in ghrelin-knockout mice, the mortality within two weeks was significantly lower in the hexarelin (6.7%) and ghrelin groups (14.3%) than in the vehicle group (50%). Furthermore, hexarelin was more effective than ghrelin as judged by the ejection fraction and other LV-dependent physiological constants as dP/dt max and dP/dt min, which is a measure of LV global contractility.48
Injections of other compounds along with IGF-1 (which is a popular practice) can also cause serious health issues. The idea is that after an user administers a GHRP (like Ipamorelin) along with IGF-1, a selective pulse is then sent that stimulates the hypothalamus and pituitary to release even more growth hormone. But this may result in an eventual negative feedback loop that leaves you unable to produce your own growth hormone and stuck on injections forever. GHRP and synthetic HGH use has also been shown to cause joint pain, huge spikes in cortisol, excessive hunger, and splitting headaches.
Growth hormone (GH) was first identified for its notable effect on longitudinal growth. Subsequent research revealed that the GH has anabolic effects on protein, lipid, and carbohydrate metabolism. GH replacement therapy, using recombinant GH, is therefore used to treat individuals with short stature due to a variety of conditions. However, GH replacement therapy suffers from significant drawbacks such as low bioavailability and side effects. Moreover, most GH-deficient individuals exhibit a secretory defect rather than a primary deficiency in GH production. Research seeking a better drug to replace GH was therefore extensively active in the 1980s and 1990s.
to amend the Standard for the Uniform Scheduling of Medicines and Poisons to include vitamin D, as a single weekly dose of up to 175 micrograms (7000IU) per recommended dose, in Schedule 3 (noting that the wording "per recommended weekly dose" in the interim decision's proposed Schedule 3 entry should have read "per recommended single weekly dose"); and
There is no “one right way”, to use Ipamorelin. For example, if you are using 500 to 1000 mcg doses daily, twice a day, your cycle might run for an 8 week period. If on the other hand, you are an athlete training for a competition, you might be on 3 injections per day, at 300-500 mcg, and will stay on for a 12 week period. For new users, you might find a 300 mcg injection is too high, and you will cut back to 200 mcg until your body gets used to it, for an 8-week cycle.
Healthy male Wistar rats (250–270 g) were purchased from the National Center for Animal Breeding (CENPALAB, Havana, Cuba). Animals were individually housed at the animals’ facility of the Center for Genetic Engineering and Biotechnology, Havana, Cuba, and maintained under controlled environmental conditions and light cycles (12/12 hrs). Rats were fed with standard laboratory rodent’s chow under no restriction. Following an acclimation week, the dorsum of the rats was conditioned to receive two controlled full-thickness wounds, under sodium pentobarbital (30 mg/kg) anesthesia. The cuts were generated with disposable 6 mm diameter punch biotomes (Acuderm, Ft. Lauderdale, USA). Two independent experiments were performed using the above described wound model. Thus, 10 rats ( wounds) were used for either GHRP-6 formulation or vehicle (1% CMC) groups in each experiment. Upon wounds induction the rats were randomly assigned to either group. The wounds were cleansed daily with saline, their contours traced on transparent plastic sheets and treated accordingly. Treatments were topically applied twice a day at the same hours during four days. Wounds closure dynamic was measured by planimetric analysis as described previously [16] using the ImageJ software, version 1.46r. Since the GHRP-6 intervention increased the rate of closure, the animals were terminated by anesthesia overdose on day five after wounding. Ulcers and a surrounding margin of intact skin (~5 mm) were collected and hemisectioned. One hemisection was preserved in RNA Later solution for further gene expression studies. The other hemisection was fixed in 10% buffered formalin, paraffin embedded, and 5-μm sectioned. The specimens were stained with hematoxylin/eosin (H/E) and Mallory trichrome to examine collagen deposit. Other slides were destined for immunohistochemistry (as described below).
It is important to understand that GHRP-6 doses on its own provides considerable HGH release from the pituitary gland, but is nowhere near as effective as the potential HGH release resultant from GHRP-6 combined with a GHRH such as Mod GRF 1-29 (CJC-1295 without DAC). Studies have demonstrated that the combination of GHRP-6 and a GHRH analogue such as Mod GRF 1-29 will generate a 77% increase in HGH output compared to GHRP-6 administration alone[8]. Other studies have gone so far as to explicitly state that GHRP-6 requires GHRH in order to stimulate maximal HGH stimulation as evidenced by the fact that in test subjects, the inclusion of a GHRH can increase HGH output by an additional 81 – 95%[9].
Figure 3: Impact of GHRP-6 treatment on wound angiogenesis. Anti-CD31 immunolabeling for mature endothelial cells. Images are representative of (a) vehicle (1% CMC)-treated wounds; (b) GHRP-6-treated wounds. No histological differences were detected between the groups in relation to the number of neovessels, their structure, distribution, organization, or CD31 positivity.
Two submissions were received, both in relation to AOD-9604. One submission did not comment on the scheduling proposal, but wished to inform the committee that the substance is an ingredient in cosmetic products being sold overseas, has an International Nomenclature Cosmetic Ingredient (INCI) name of 27701 sh-Oligopeptide-74 and is published in the International Cosmetic Ingredient Dictionary and Handbook as well as the International Buyer's Guide.
Just as the name suggests, GHRH helps to stimulate secretion of growth hormone. The duration of secretion induced will depend on the specific type of peptide that you use. An important thing to note here is that these substances are effective only to a limit. Exceeding the saturation dose, which may vary between individuals, will not improve the amount of HGH that is secreted. Below are a few peptides that fall in the GHRH group.
A SARM (an acronym for "Selective Androgen Receptor Modulator") is a drug that is chemically similar to anabolic steroids but with reduced androgenic properties. The main advantages SARMs have over anabolic steroids are androgen-receptor specificity, tissue selectivity, and reduced side effects. SARMs also have the ability to differentiate between anabolic and androgenic activities, whereas steroids do not.

You’ve already learned that sufficient protein intake (above 0.5g/lb of body weight) can assist with adequate IGF-1 and growth hormone production. Whey protein provides your body with a complete profile of necessary amino acids, including leucine. Leucine is an amino acid that promotes greater muscle protein synthesis and assists the body while gaining lean muscle mass and losing fat tissue simultaneously.


If you’re looking to increase your muscle growth and improve strength, whether for competitive bodybuilding or to achieve a personal physique goal, our Australian muscle building peptide supplements can help. Our dedicated research and product development team have consistently produced new products that perform better than other supplement brands, so you know you’ll be getting the best peptide supplements available. If you’re new to peptide supplements and have questions, read our FAQ’s, or alternatively email us at info@musclepeptidesaustralia.com.au and our clinic doctor can help you with your questions.
"From the 1st click, my experience with Elite Sarms was great. My order was confirmed within seconds, packed & shipped that day, & delivered so quickly! Hyper Lean was my first sarms experience, & noticed an effect within a couple days. My diet has remained constant - food groups, cals, macro ratios - all the same - & have really leaned out in a short time! My body resisted change for months of dieting, carb cycling, & various training forms - up & down, & my constant stress levels didn't help at all. But with Hyper Lean I've found it does exactly what it says it does - metabolism is up as I drop fat & increase mass. I've had no negative side effects. And the strength - I find that the metabolism boost aids my recovery & my energy output, despite being in a slight caloric deficit I'm gaining muscle, and my previous PRs are history - after 6 months of struggles I feel like an athlete again! Thanks Elite Sarms - I'm impressed! " EP

The availability of a pack size of 28 days' supply may result in the whole pack being used regardless of the pack being labelled with "14 day treatment". Consumers who initiate this treatment in a pharmacy setting may not see a medical practitioner for a month. If a consumer has not responded to treatment after 14 days, it is a flag for them to seek further medical assessment.

There are some alternatives to GHPR-6 in the market which are easier to procure and considered legal in many countries. Natural supplements consisting of amino acids which are safer and non-hormonal when brought together may facilitate the increase of natural manufacturing of HGH. The effectiveness of these alternatives are likely to be inferior to the real deal but you should consider them if you are unlikely to get your hands on that precious prescription. Do a bit of research on your own and try finding the best option for you.


Ryan also brings up a good point to bring up the fact that GHRH receptors are typically not desensitized with higher dosing but again not much accomplished with CJC-1295, ,MOD GRF 1-29 where we know the 100mcg is a saturation dose. on the other hand we can desensitize the GHRP receptor if we start increasing the dosing significantly above the saturation dosing  of 100mcg. I think you are fine at a 150 mcg dosing but again how much more benefit are you really getting.
The delegates have decided that the wording of the interim decision to list the highest strength teeth whitening preparations in Appendix C is to be amended to remove the restriction "for direct in-clinic use". The delegates considered this to be too restrictive to dental practitioners in the exercise of their professional practice* and it did not accurately reflect the advice of the expert advisory committees. This approach was supported by all but one submission received during the consultation on the interim decision, with the exception of a wording change to reflect that the intent was not to limit the way dental practitioners use such products in exercising their professional practice.
It is both impractical and impossible to categorize GHRP-6 doses into the typical three tiers of users (beginner, intermediate, and advanced) due to the inherent nature of the type of substance and hormone. The saturation doses of GHRP-6 should elicit significant increases in HGH levels in the body in a pulsatile manner that is adequate enough to ensure any performance and physique enhancing goals desired by any individual. The difference in which goals might be more attainable than others is the frequency of dosing. GHRP-6 exhibits a varying half-life of approximately 15 – 60 minutes after injection, and will stimulate a large pulse of HGH from the pituitary gland that will last several hours but is most intense and achieves its peak at approximately 30 minutes. Therefore, in order to simulate higher and steadier blood plasma levels of HGH, it is necessary to administer GHRP-6 doses multiple times daily (depending on the user’s goals).
The final verdict is to go for it. GHRP-6 is not your garden-variety performance enhancer. One of the most important aspects of it is that it does not cause desensitization. This means that it will not cause overdose and that works best for athletes. Also since it increases appetite, it forces you to make more calories available to your body for exercise and for recovery. It does not boost unnatural muscle growth like other performance enhancers and the result does not put extra pressure on your tendons and ligaments.

The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.

Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.

SARMs stimulate androgen receptors specifically in muscle and bone cells, hence assisting with muscle and bone growth, while having little effect on the other cells in the body (unlike regular steroids). They have a special affinity for certain tissues like muscle and bone, but not for others, like the prostate, liver, and brain. This means more rapid muscle and bone growth without unwanted growth in other parts of your body.

Phenylephrine is readily eliminated by sulphate conjugation in the intestinal wall, and oxidative deamination by monoamine oxidative glucuronidation in the liver. Monoamine oxidase (MAO) inhibitors can enhance the limited potential of phenylephrine for cardiac and pressor effects, by reducing metabolism. As a largely specific alpha adrenergic drug, with very weak beta agonism, there is little direct cardiac effect. However, in higher doses, there can be increases in both systolic and diastolic blood pressure and a reflex bradycardia. As an adrenergic agonist there is the potential to interact with other sympathomimetic drugs. In overdose phenylephrine can cause hypertension, headaches seizures tachycardia, and vomiting. There has been no evidence from carcinogenicity studies in rodents of any enhanced cancer risk over prolonged exposure.
It is also important to note that whether you are a long-time user or a first-time user of Ipamorelin, your body is going to react differently to that of the next user. Like the benefits you will experience, the side effects you are going to experience will occur differently, and at different dosage levels. So, it truly is a trial and error period you are going to go through with a test run of Ipamorelin for new users. You have to find what works for you, how your body will react, and what potential side effects are lingering ahead, in order for you to achieve the greatest results, and eventually find the proper dosage and cycle level, which is going to work the best for your body and system.
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
Extreme hunger stimulation: It has been previously mentioned in this profile already that almost all GHRPs will stimulate hunger simply by virtue of the fact that they are Ghrelin mimetics (they mimic the action of the hormone Ghrelin in the body), but GHRP-6 has demonstrated both anecdotally as well as clinically to stimulate the largest hunger increases in comparison to all other GHRPs[2]. GHRP-6 tends to stimulate what can only be described as agonizing hunger, and is commonly misconceived as a hypoglycemic episode. The hunger resultant from GHRP-6 is, in fact, simply the peptide acting on Ghrelin receptors that signal hunger to various regions in the brain. No studies or any anecdotal evidence demonstrates hypoglycemic blood glucose readouts following GHRP-6 administration. Following a meal, the hunger should subside. Many users have also reported the intensity of the hunger diminishing several weeks into GHRP-6 cycles but not completely disappearing.
The original GRF (1-29) has a half-life of about 30 minutes. Half-life means the time within which half of the hormone administered will be destroyed within the body. This short half-life is due to the fact that the compound is highly unstable and breaks down soon. To increase its stability and to make it last longer, it was modified by adding 4 amino acids in its structure. This gave it the name Modified GRF (1-29) or Mod GRF 1-29. It was originally invented by DatBtrue. The portion of the molecule that actually stimulates the growth hormone secretion is found in the chain of 29 amino acids, so it is named GRF (1-29). This chemical also produces slow-wave sleep.
This is the most popular variant of IGF-1 that buyers will find on the market today. IGF-1 LR3 comprises 83 amino acids. That means it adds extra 13 amino acids to the sequence of the standard insulin-like growth factor-1. The polypeptide boasts qualities that make it much more powerful than normal IGF-1. It boasts a longer half life of up to 30 hours, compared to the latter’s 15 hours. In addition to bodybuilding, IGF-1 LR3 helps with fat burning, quicker recovery and slowing aging.
Technically, it is a “protein-peptide hormone” which means that it consists of 70 amino acids bonded together. Just like the peptides I’ve written about in the past, this means that it must be injected, because otherwise IGF-1 simply degrades in the gut, rendering it useless. Your own human growth hormone release promotes the synthesis of IGF-1 in your liver (and to smaller amounts, synthesis of IGF-1 by your muscles), your liver and muscles then synthesize IGF-1 and then, in the case of your liver, subsequently package the IGF-1 with binding proteins for transport into the blood. In a type of anabolic positive-feedback loop, IGF-1 then further increases growth hormone’s anabolic effects.
Figure 4: Influence of GHRP-6 on the expression of different gene families. RT-PCR experiments demonstrate the GHRP-6-induced reduction of the expression of its own receptor (Cd36). Concurrently, the peptide significantly reduced proinflammatory and profibrogenic cytokines. It is likely that the attenuation of these fibrogenic growth factors accounted for a reduction of extracellular matrix proteins and mesenchymal cells cytoskeleton proteins. Unpaired -test (, , and ).
Extreme hunger stimulation: It has been previously mentioned in this profile already that almost all GHRPs will stimulate hunger simply by virtue of the fact that they are Ghrelin mimetics (they mimic the action of the hormone Ghrelin in the body), but GHRP-6 has demonstrated both anecdotally as well as clinically to stimulate the largest hunger increases in comparison to all other GHRPs[2]. GHRP-6 tends to stimulate what can only be described as agonizing hunger, and is commonly misconceived as a hypoglycemic episode. The hunger resultant from GHRP-6 is, in fact, simply the peptide acting on Ghrelin receptors that signal hunger to various regions in the brain. No studies or any anecdotal evidence demonstrates hypoglycemic blood glucose readouts following GHRP-6 administration. Following a meal, the hunger should subside. Many users have also reported the intensity of the hunger diminishing several weeks into GHRP-6 cycles but not completely disappearing.
The impact of the treatment on the neodermal matrix reconstitution was qualitatively graded as described [17, 18]:(0)Immature granulation tissue with a null or incipient formation of collagen fibrils, focally distributed with no alignment and not organized meshwork. Fibrin material prevails in the field. Mallory staining is detected in scarce foci.(1)Scarce collagen fibrils suggestive of a primitive degree of organization, focally distributed, without horizontal alignment along the wound bed. Yet, fibrin occupies more than 50% of the field. Limited number of primitive neoformed vessels with empty lumen. Relative increase of positivity to Mallory staining.(2)A general but coarse image of ECM granulation tissue accumulation, containing intermixed vertically and horizontally oriented collagen fibrils. Full replacement of fibrin by collagen. Fibrin has been fully replaced by collagen. Affinity to Mallory staining is observed.(3)Complete ECM reconstitution, with mature and finely organized collagen fibrils horizontally deposited in the neodermis. The whole matrix appears positive to Mallory staining.
However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce.
In studies of the opioid control of GH secretion, several peptide analogues of met-enkephalin were found to be potent GH secretagogues. These include the GH-releasing peptide GHRP-6 (Fig. 7-21), hexarelin (His-d2MeTrp-Ala-Trp-dPhe-Lys-NH2), and other more potent analogues including cyclic peptides and modified pentapeptides. Subsequently, a series of nonpeptidyl GHRP mimetics were synthesized with greater oral bioavailability, including the spiropiperidine MK-0677 and the shorter acting benzylpiperidine L-163,540 (see Fig. 7-21). Common to all these compounds, and the basis of their differentiation from GHRH analogues in pharmacologic activity screens, is their activation of phospholipase C and inositol 1,4,5-trisphosphate. This property was exploited in a cloning strategy that led to the identification of a novel GPCR GHS-R that is highly selective for the GH secretagogue class of ligands. The GHS-R is unrelated to the GHRH receptor and is highly expressed in the anterior pituitary gland and multiple brain areas, including the medial basal hypothalamus, the hippocampus, and the mesencephalic nuclei that are centers of dopamine and serotonin production.

CJC-1295 increases the production of growth hormone as well as IGF-1 – which has anabolic effects in adults. However, it does not increase the levels of prolactin – high levels of which can create impotence and mental health problems in men. By increasing these two hormones, it enhances protein production in the body, which in turn, boosts muscle mass. It also induces lipolysis – the breakdown of fat tissue, boosts recovery from injuries, increases bone density, and also reduces aging factors like skin wrinkles. It can also stimulate cell growth, due to which it can be used to treat withered tissue or organs.


Used for muscle building, weight loss and anti-aging purposes, this is a very powerful peptide for promoting growth hormone release. GHRP-6 also helps in fighting inflammation and boosting recovery. Some professional bodybuilders are believed to use it together with steroids for greater potency. The peptide not only stimulates the pituitary to produce growth hormone, but also suppresses somatostatin which could impede release.
Figure 4: Influence of GHRP-6 on the expression of different gene families. RT-PCR experiments demonstrate the GHRP-6-induced reduction of the expression of its own receptor (Cd36). Concurrently, the peptide significantly reduced proinflammatory and profibrogenic cytokines. It is likely that the attenuation of these fibrogenic growth factors accounted for a reduction of extracellular matrix proteins and mesenchymal cells cytoskeleton proteins. Unpaired -test (, , and ).

If you are an athlete or a bodybuilder looking for ways to decrease body fat whilst increasing muscle mass then GHRP 2 and GHRP 6 (the two types of Growth Hormone Releasing Peptides) can certainly help you with your requirements. The best part with these hormones is that you are likely to get the desired results out of them, especially when you combine them with muscle building and fat-burning foods, aerobic and intense strengthening exercises. However, there are subtle differences between the two hormones that you cannot ignore. 
×